HS
PLRX icon

HighVista Strategies’s Pliant Therapeutics PLRX Stock Holding History

HighVista Strategies’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-109,938
Closed -$148K – 169
2025
Q1 		$148K Buy
+109,938
New +$667K 0.06% 148
2024
Q2 		– Sell
-34,039
Closed -$507K – 153
2024
Q1 		$507K Hold
34,039
– – 0.18% 119
2023
Q4 		$616K Buy
34,039
+3,316
+11% +$50.4K 0.22% 112
2023
Q3 		$533K Sell
30,723
-3,312
-10% -$57.4K 0.25% 100
2023
Q2 		$617K Hold
34,035
– – 0.28% 112
2023
Q1 		$905K Sell
34,035
-7,427
-18% -$211K 0.74% 40
2022
Q4 		$801K Buy
+41,462
New +$867K 0.48% 63

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

HighVista Strategies's PLRX Position: Q2 2025 in Review

HighVista Strategies sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 109,938 shares — an estimated $148K sold.

HighVista Strategies first reported a position in PLRX in Q4 2022 and held it in 7 quarters. The position peaked at $905K in Q1 2023. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • HighVista Strategies reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HighVista Strategies sold 109,938 Pliant Therapeutics shares in Q2 2025, an estimated $148K.
  • HighVista Strategies first reported a position in Pliant Therapeutics in Q4 2022 and held it in 7 quarters.
  • HighVista Strategies's Pliant Therapeutics position peaked at $905K in Q1 2023.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.